Abstract
There are numerous inborn errors of metabolism of the liver, and they are all rare to very rare. To get a clear picture of the indications for gene transfer in these conditions, it is essential to get a clear view on the current (lack of) insight in the pathophysiology of these disorders, the current treatment options and hence on the window of opportunity for new treatments as gene transfer. The aim of this review, is to illustrate the problems related to treatment of inborn errors of metabolism of the liver. General aspects defining the quest for treatments for very rare diseases are touched upon, but for the sake of clarity, this review is restricted to five illustrative examples: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia and propionic acidemia. These examples reflect the problems that are currently experienced and can be expected, when gene transfer trials for these disorders are undertaken.
Keywords: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia, propionic academia, phototherapy, bilirubin, cirrhosis, phenylalanine hydroxylase gene, Propionic acidemia
Current Pharmaceutical Design
Title: Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective
Volume: 17 Issue: 24
Author(s): David Cassiman
Affiliation:
Keywords: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia, propionic academia, phototherapy, bilirubin, cirrhosis, phenylalanine hydroxylase gene, Propionic acidemia
Abstract: There are numerous inborn errors of metabolism of the liver, and they are all rare to very rare. To get a clear picture of the indications for gene transfer in these conditions, it is essential to get a clear view on the current (lack of) insight in the pathophysiology of these disorders, the current treatment options and hence on the window of opportunity for new treatments as gene transfer. The aim of this review, is to illustrate the problems related to treatment of inborn errors of metabolism of the liver. General aspects defining the quest for treatments for very rare diseases are touched upon, but for the sake of clarity, this review is restricted to five illustrative examples: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia and propionic acidemia. These examples reflect the problems that are currently experienced and can be expected, when gene transfer trials for these disorders are undertaken.
Export Options
About this article
Cite this article as:
Cassiman David, Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective, Current Pharmaceutical Design 2011; 17 (24) . https://dx.doi.org/10.2174/138161211797247596
DOI https://dx.doi.org/10.2174/138161211797247596 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking
Current Genomics Low Molecular Weight Heparins and Glomerular Filtration Rate: A Report to be Considered
Current Vascular Pharmacology Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry Targeting Prenylated RAS Modifying Enzymes in Cancer Cells
Current Signal Transduction Therapy Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Regulation of Inflammation and Myocardial Fibrosis in Experimental Autoimmune Myocarditis
Inflammation & Allergy - Drug Targets (Discontinued) Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology Building Mosaics of Therapeutic Plasmid Gene Vectors
Current Gene Therapy Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events
Current Pharmaceutical Design A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Current Pharmaceutical Design Small Heat Shock Proteins and the Endoplasmic Reticulum: Potential Attractive Therapeutic Targets?
Current Molecular Medicine Potential Impact of Genetic Variants in Nrf2 Regulated Antioxidant Genes and Risk Prediction of Diabetes and Associated Cardiac Complications
Current Medicinal Chemistry Urine Cells-derived iPSCs: An Upcoming Frontier in Regenerative Medicine
Current Medicinal Chemistry A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges
Current Gene Therapy